SCFAs switch stem cell fate through HDAC inhibition to improve barrier integrity in 3D intestinal organoids from patients with obesity.

Behavioral neuroscience Biological sciences Neuroscience

Journal

iScience
ISSN: 2589-0042
Titre abrégé: iScience
Pays: United States
ID NLM: 101724038

Informations de publication

Date de publication:
15 Dec 2023
Historique:
received: 03 07 2023
revised: 25 07 2023
accepted: 20 11 2023
medline: 21 12 2023
pubmed: 21 12 2023
entrez: 21 12 2023
Statut: epublish

Résumé

Stem cells are a keystone of intestinal homeostasis, but their function could be shifted during energy imbalance or by crosstalk with microbial metabolites in the stem cell niche. This study reports the effect of obesity and microbiota-derived short-chain fatty acids (SCFAs) on intestinal stem cell (ISC) fate in human crypt-derived intestinal organoids (enteroids). ISC fate decision was impaired in obesity, resulting in smaller enteroids with less outward protruding crypts. Our key finding is that SCFAs switch ISC commitment to the absorptive enterocytes, resulting in reduced intestinal permeability in obese enteroids. Mechanistically, SCFAs act as HDAC inhibitors in stem cells to enhance Notch signaling, resulting in transcriptional activation of the Notch target gene HES1 to promote enterocyte differentiation. In summary, targeted reprogramming of ISC fate, using HDAC inhibitors, may represent a potential, robust therapeutic strategy to improve gut integrity in obesity.

Identifiants

pubmed: 38125020
doi: 10.1016/j.isci.2023.108517
pii: S2589-0042(23)02594-4
pmc: PMC10730380
doi:

Types de publication

Journal Article

Langues

eng

Pagination

108517

Informations de copyright

© 2023 The Authors.

Déclaration de conflit d'intérêts

The authors declare no conflicts of interest.

Auteurs

Mona Farhadipour (M)

Gut Peptide Research Lab, Translational Research for Gastrointestinal Disorders (TARGID), KU Leuven, 3000 Leuven, Belgium.

Kaline Arnauts (K)

Inflammatory Bowel Disease, Translational Research for Gastrointestinal Disorders (TARGID), KU Leuven, 3000 Leuven, Belgium.

Mathias Clarysse (M)

Leuven Intestinal Failure and Transplantation (LIFT) Center, University Hospitals Leuven, 3000 Leuven, Belgium.

Theo Thijs (T)

Gut Peptide Research Lab, Translational Research for Gastrointestinal Disorders (TARGID), KU Leuven, 3000 Leuven, Belgium.

Kathrin Liszt (K)

Gut Peptide Research Lab, Translational Research for Gastrointestinal Disorders (TARGID), KU Leuven, 3000 Leuven, Belgium.

Bart Van der Schueren (B)

Department of Endocrinology, University Hospitals Leuven, 3000 Leuven, Belgium.

Laurens J Ceulemans (LJ)

Leuven Intestinal Failure and Transplantation (LIFT) Center, University Hospitals Leuven, 3000 Leuven, Belgium.

Ellen Deleus (E)

Department of Abdominal Surgery, University Hospitals Leuven, 3000 Leuven, Belgium.

Matthias Lannoo (M)

Department of Abdominal Surgery, University Hospitals Leuven, 3000 Leuven, Belgium.

Marc Ferrante (M)

Inflammatory Bowel Disease, Translational Research for Gastrointestinal Disorders (TARGID), KU Leuven, 3000 Leuven, Belgium.
Department of Gastroenterology and Hepatology, University Hospitals Leuven, 3000 Leuven, Belgium.

Inge Depoortere (I)

Gut Peptide Research Lab, Translational Research for Gastrointestinal Disorders (TARGID), KU Leuven, 3000 Leuven, Belgium.

Classifications MeSH